Eli Lilly and Co. (LLY) said Tuesday that the Phase 3 BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance.
According to the company, its neutralizing antibodies Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19 by 70 percent, and met the primary endpoint of the Phase 3 BLAZE-1 trial.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com